To synthesize current clinical and experimental evidence on the renal impact of biologics used in psoriasis management and to provide a theoretical basis for the rational selection of biologic therapies in patients with renal concerns.
Approach:
Key Findings:
Biologics do not appear to increase CKD incidence compared to conventional therapies like methotrexate.
Case reports indicate successful use of biologics in patients with ESRD or IgA nephropathy.
Chronic systemic inflammation from psoriasis contributes to renal injury and functional decline.
Interpretation:
The findings suggest that while biologics are effective for psoriasis, their renal safety profile requires careful consideration, especially in patients with pre-existing renal conditions.
Limitations:
Limited longitudinal data on renal outcomes in biologic-treated psoriasis patients.
Variability in reported incidence of CKD among psoriatic patients.
Conclusion:
A multidisciplinary approach is essential to tailor biologic treatments that maximize efficacy while minimizing renal adverse effects, particularly in patients with existing renal comorbidities.
